Neurorehabilitation Department
Pavia, 27100, Italy
NCT Number: NCT04620863
Pisa Syndrome (PS) is a lateral trunk flexion frequently associated to Parkinson's disease (PD). The management of PS is still a challenge for the clinician, because it poorly responds to anti-parkinsonian drugs, and the improvement achieved with neurorehabilitation or botulinum toxin injections tends to fade in 6 months or less. Transcranial direct current stimulation (t-DCS) is a non-invasive neuromodulation technique, with promising results in movement disorders. Aim of our study is to evaluate the role of bi-hemispheric t-DCS as add-on to neurorehabilitation in PS. Twenty-eight patients affected by PD and PS were managed with a 4-week hospital neurorehabilitation programme and randomized to: 1) t-DCS group: 5 daily sessions (20 minutes - 2 mA) with cathode over the primary motor cortex (M1) contralateral to PS, and anode over the M1 cortex ipsilateral to PS; or 2) sham group. Patients were tested with kinematic analysis of trunk movement in static and dynamic conditions, UPDRS-III, FIM, and VAS for lumbar pain rating at hospital admission (T0), at hospital discharge (end of neurorehabilitation - T1), and 6 months later (T2). At T0, the evaluations were completed by an EMG study of trunk muscles activation.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Pavia, 27100, Italy
Axial disorders are frequent complications of Parkinson's Disease (PD) and they can lead to postural deformities and balance impairments. The most prevalent postural disorders of PD are represented by camptocormia, antecollis, scoliosis, and Pisa syndrome (PS).
The pathogenesis of these disorders has not yet been completely elucidated, and it is characterized by a complex interlacement between central and peripheral mechanisms.
The first report of PS dates back in 1972, when Ekobm described a case series of three patients who developed a lateral trunk flexion in close temporal relationship with neuroleptics assumption. The roster of drugs associated with an acute/subacute onset of PS is huge and constantly growing, and it includes: antidepressants (mirtazapine, sertraline), cholinesterase inhibitor (rivastigmine, galantamine, donepezil), neuroleptics (tiapride, clotiapine, clozapine, aipiprazole, butyrophenone, paliperidone, quetiapine), dopamine agonists, (pramipexolo, ropinirole, pergolide), lithium, valproic acid, and betahistine. Nonetheless, PS was described as well in patients with neurodegenerative disorders, and in particular in PD and parkinsonism without drugs exposure.
The prevalence of PS is around 8.3% (9.3% in women and 6.4% in men) when calculated in a psychogeriatric population, and it is 8 to 8.8% when populations of PD patients were considered.
Formal diagnostic criteria for PS are not available, indeed the diagnosis is based on the clinical features:
The fluctuation of the postural alteration during static (supine position vs. upright standing position) and dynamic conditions appears to be crucial to differentiate PS from scoliosis.
A lateral trunk deviation of at least 10° is commonly accepted for the diagnosis, although higher or lower cut-offs were used in the past. According to the degree of the lateral trunk flexion, PS can be further divided in mild (less than 20°) or severe (more than 20°) phenotypes.
Patients with PD and PS showed some typical clinical and demographic features when compared to PD patients without postural alterations: they are older, PD is longer in duration, more severe and with a more pronounced asymmetry of motor symptoms. The parkinsonian symptoms involving the upper limbs as well as gait impairment are more severe in PD patients with PS. Moreover, they are characterized by a higher incidence of falls, arthrosis, osteoporosis, orthopedics diseases and pain, specifically lumbar and lower back pain, which is reported in up to 75% of patients with PD and PS.
The management of PS is still a challenge for the physician. PS poorly responds to antiparkinsonian drugs, although there aren't studies specifically designed to assess this topic.
Neurorehabilitation represents one of the fundamental approach to PD and to postural disorders in general, not only for the treatment of the motor symptoms itself but also to improve quality of life and autonomy in the activity of daily living.
The study was a randomized, double-blind, controlled trial aimed to assess the efficacy of five daily sessions of bi-hemispheric t-DCS in add-on to an in-hospital neurorehabilitation protocol in patients affected by PD and PS.
At hospital admission (T0 - baseline), all patients underwent complete neurological, general and functional examinations by a Neurologist with expertise in movement disorders and neurorehabilitation. Patients who fulfilled inclusion and exclusion criteria underwent a baseline kinematic analysis of trunk movement. Patients with at least 10° of lateral trunk flexion completed the baseline evaluations with a dynamic electromyographic (EMG) study of trunk muscles, and with administration of a set clinical scales for the evaluations of motor disability, functional independence, and lumbar pain.
After that, patients were randomly assigned to "t-DCS" or "sham" treatment, and they started the double-blind phase of the study. The 5-day t-DCS/sham treatment was delivered in 5 daily consecutive sessions, starting from the first Monday after hospital admission. In parallel to neuromodulation, all patients were treated with a standardized 4-week rehabilitation programme. The kinematic analysis of trunk movement as well as the administration of the set of questionnaires were repeated at the end of the 4-week rehabilitation programme (T1 - hospital discharge), and 6 months after discharge (T2).
The randomization was performed according to a block randomization method. A unique randomization list was generated before enrollment with the following parameters: 6 blocks; 6 patients per block (3 for t-DCS group, and 3 for sham group).
All the patients were treated with an optimized and individualized anti-parkinsonian therapy, which dose and regimen were kept stable during the overall study period. All the evaluations were performed in the morning, and always in an ON phase.
The specific and standardized in-hospital rehabilitation programme was focused on the rehabilitation of the trunk postural disorder. All patients were treated with 90-minute daily sessions, 6 days a week (Monday to Saturday) for four weeks.
Each session was structured as follow:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Thirty patients affected by Parkinson' Disease (PD) and Pisa Syndrome (PS) were consecutive enrolled among those attending the Neurorehabilitation Department of the IRCCS Mondino Foundation (Pavia, Italy). Idiopathic PD was diagnosed according to the Movement Disorders Society clinical diagnostic criteria for PD. Pisa syndrome was clinically diagnosed according to the following criteria:
All the participants received daily stimulation sessions for 5 consecutive days, starting from the first Monday after hospital admission (Monday to Friday). The primary motor cortex (M1) was identified using the International 10-20 system for C3 (left M1) or C4 (right M1). For the stimulation, the anode was placed over the primary motor cortex (M1) ipsilateral to the side of trunk deviation, and the cathode was placed over the primary motor cortex (M1) contralateral to the side of trunk deviation (bi-hemispheric stimulation).
The stimulation setting was exactly the same but the stimulation intensity was set according to a ramping up/ramping down method and delivered only in the first and last 30 seconds of each session. This stimulation paradigm is insufficient to produce a meaningful therapeutic effect, but it is necessary to guarantee the blind condition as it mimics the possible initial tingling sensation associated with active stimulation.
Time frame: Change from Baseline at 28 weeks (T2)
Total postural alteration in the upright standing position (Stat Tot): lateral trunk inclination in the upright standing position (Stat Bend) plus anterior trunk flexion in the upright standing position (Stat Flex).
Time frame: Change from Baseline at 28 weeks (T2)
Lateral trunk inclination in the upright standing position
Time frame: Change from Baseline at 28 weeks (T2)
Anterior trunk flexion in the upright standing position
Time frame: Change from Baseline at 28 weeks (T2)
Range of Motion (ROM) of trunk bending ipsilateral to the side of trunk deviation
Time frame: Change from Baseline at 28 weeks (T2)
Range of Motion (ROM) of trunk bending contralateral to the side of trunk deviation
Time frame: Change from Baseline at 28 weeks (T2)
Range of Motion (ROM) of anterior trunk flexion
Time frame: Change from Baseline at 28 weeks (T2)
Range of Motion (ROM) of posterior trunk extension
Time frame: Change from Baseline at 28 weeks (T2)
ROM Ips + ROM Con + ROM Flex + ROM Ext
Time frame: Change from Baseline at 28 weeks (T2)
It consists of 18 items (score from 0 to 4). Higher scores are worst otcomes.
Time frame: Change from Baseline at 28 weeks (T2)
The Functional Independence Measure (FIM) is an 18-item measurement tool that explores an individual's physical, psychological and social function. FIM scores range from 1 to 7 (1= total assist and 7= complete independence).
Time frame: Change from Baseline at 28 weeks (T2)
Lumbar pain severity was rated according to a 0 to 10 visual analog scale. Zero is no pain and 10 is worst pain.
IRCCS National Neurological Institute "C. Mondino" Foundation
Other
TRANSCRANIAL DIRECT CURRENT STIMULATION (t-DCS) AS ADD-ON TO NEUROREHABILITATION OF PISA SYNDROME IN PARKINSON DISEASE: A RANDOMIZED CONTROLLED TRIAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07010328
Basal Ganglia Diseases, Behavior
Pavullo nel Frignano, Pavia, Italy
View Trial DetailsNCT06133283
Basal Ganglia Diseases, Brain Diseases
San Antonio, Texas, United States
View Trial DetailsNCT05766813
Basal Ganglia Diseases, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07723027
Basal Ganglia Diseases, Brain Diseases
Shakargarh, Punjab Province, Pakistan
View Trial Details